While it no longer generates the sales it once did, Pfizer's coronavirus lineup remains critical to its results. The past ...

Previously, updated COVID vaccines had been recommended annually by the CDC for everyone over the age of 6 months. The CDC ...

The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.

The US Food and Drug Administration may limit Covid-19 boosters shots to high-risk groups from 2025; Pfizer reviewing proposal as agency seeks new trials, clearer risk labels for younger males ...

A new COVID variant has been reported in China, which could lead to another round of COVID booster shots in America.

The FDA had given Pfizer and Moderna until May 17 to propose changes to the labels of their COVID-19 vaccines or challenge ...

Investors reacted favorably to the news and shares of COVID vaccine makers rose. In late morning trading, shares of Moderna ...

There is no “the” vaccine. There are at least two mRNA vaccines (Moderna and Pfizer) and a number of different non-mRNA ...

The move effectively limits the booster’s availability later this year to older adults and those at risk of developing severe ...

Shares of Moderna surged to lead S&P 500 gainers Tuesday after the Food and Drug Administration issued new guidance for COVID ...